QCM
CRNX

Quantinno Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Quantinno Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
27,741
-5,993
-18% -$223K ﹤0.01% 2522
2026
Q1 		$1.23M Buy
33,734
+24,878
+281% +$1.11M ﹤0.01% 1989
2025
Q4 		$412K Buy
8,856
+1,049
+13% +$46.7K ﹤0.01% 2610
2025
Q3 		$325K Buy
7,807
+507
+7% +$16.2K ﹤0.01% 2396
2025
Q2 		$210K Buy
+7,300
New +$225K ﹤0.01% 2326

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantinno Capital Management's CRNX Position: Q2 2026 in Review

Quantinno Capital Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 18% in Q2 2026, selling an estimated $223K and leaving 27,741 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2522.

Quantinno Capital Management first reported a position in CRNX in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.23M in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Quantinno Capital Management held 27,741 shares of Crinetics Pharmaceuticals worth $1.04M as of Q2 2026.
  • Quantinno Capital Management sold 5,993 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $223K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2522 holding.
  • Quantinno Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Quantinno Capital Management's Crinetics Pharmaceuticals position peaked at $1.23M in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.